We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SpyGlass Combo Glaucoma Treatment Almost Halves Intraocular Pressure in Study
SpyGlass Combo Glaucoma Treatment Almost Halves Intraocular Pressure in Study
A first-in-human feasibility trial of SpyGlass Pharma’s combination product to treat glaucoma led to a 45 percent drop in patients’ mean intraocular pressure at three months without the need for additional therapy, the company said at the American Academy of Ophthalmology annual meeting in Chicago.